Company: NCEL
Filing Date: 2025-10-17
Form Type: POS AM
Source: 0001213900-25-099986
Chunk: 15

Company: NewcelX Ltd.
Filing Date: 2025-10-17
Form: POS AM
Chunk 15
---
 a rate of 0.1% (cantonal and communal tax only, as there is no federal tax on capital). Value Added Tax, or VAT, is charged on all qualifying goods and services by VAT -registeredbusinesses. An amount of 8.1% of the value of the goods or services is added to all sales invoices and is payable to the Swiss tax authorities. Similarly, VAT paid on purchase invoices is reclaimable from the Swiss tax authorities. Results of Operations The numbers below have been derived from our unaudited interim condensed financial statements included elsewhere in this Report on Form 6 -K. The discussion below should be read along with these financial statements, and it is qualified in its entirety by reference to them. Comparison of the Six Months Ended June 30, 2025 and 2024

|                                     |     | For the Six Months Ended 
 June 30,                 |       2025 |   |     |   |       2024 |   |
|:------------------------------------|:----|:-------------------------|-----------:|:--|:----|:--|-----------:|:--|
| Research and development expenses   |     | $                        |    142,083 |   |     | $ |    271,350 |   |
| General and administrative expenses |     |                          |  1,637,132 |   |     |   |  1,782,142 |   |
| Merger transaction costs            |     |                          |    420,289 |   |     |   |          — |   |
| Operating loss                      |     |                          | (2,199,504 | ) |     |   | (2,053,492 | ) |
| Other income (expense), net         |     |                          |    (20,782 | ) |     |   |    104,643 |   |
| Interest on related party loans     |     |                          |       (385 | ) |     |   |    (86,985 | ) |
| Net loss                            |     | $                        | (2,220,671 | ) |     | $ | (2,035,834 | ) |

7

Research and Development Expenses Research and development activities are essential to our business and historically represented the majority of our costs incurred. Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using information from the clinical sites and our vendors. In